Mucus hypersecretion in copd: Should we only rely on symptoms?

European Respiratory Review

Volumn 19, Issue 116, 2010, Pages 94-96

  Burgel, P R ^a   Martin, C ^a  

^a Assistance Publique Hôpitaux de Paris ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CARBOCISTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN; MUCOLYTIC AGENT; STEROID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COUGHING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG TARGETING; GOBLET CELL; HISTOPATHOLOGY; HUMAN; MUCOCILIARY CLEARANCE; MUCUS HYPERSECRETION; MUCUS SECRETION; REVIEW; SPUTUM; SYMPTOMATOLOGY;

AIRWAY OBSTRUCTION; COUGH; HUMANS; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77953228164     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00004410     Document Type: Review

References (25)

1. Cerveri I, Brusasco V. Revisited role for mucus hypersecretion in the pathogenesis of COPD. Eur Respir Rev 2010; 19: 109-112.
2. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010; 19: 127-133.
3. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev 2010; 19: 134-140.
4. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
5. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535.
6. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364.
7. Pelkonen M, Notkola IL, Nissinen A, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle- aged rural men. Chest 2006; 130: 1129-1137.
8. Lange P, Nyboe J, Appleyard M, et al. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45: 579-585.
9. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98-107.
10. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-982.
11. Melton L. Does mucus hypersecretion matter in airway disease? Lancet 2002; 359: 1924.
12. Mullen JBM, Wright JL, Wiggs B, et al. Reassessment of inflammation in the airways in chronic bronchitis. BMJ 1985; 291: 1235-1239.
13. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
14. Innes AL, Woodruff PG, Ferrando RE, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006; 130: 1102-1108.
15. O'Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 2004; 59: 1032-1040.
16. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
17. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176: 454-459.
18. Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004; 45: 477-484.
19. Burgel PR, Nadel JA. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 2008; 32: 1068-1081.
20. Burgel PR, Cardell LO, Ueki IF, et al. Intranasal steroids decrease eosinophils but not mucin expression in nasal polyps. Eur Respir J 2004; 24: 594-600.
21. Randell SH, Boucher RC. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35: 20-28.
22. Innes AL, Carrington SD, Thornton DJ, et al. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med 2009; 180: 203-210.
23. Curran DR, Cohn L. Advances in mucous cell metaplasia: a plug for mucus as a therapeutic focus in chronic airway disease. Am J Respir Cell Mol Biol 2010; 42: 268-275.
24. Woodruff PG, Wolff M, Hohlfeld JM, et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 438-445.
25. Singer M, Martin LD, Vargaftig BB, et al. A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma. Nat Med 2004; 10: 193-196.